Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms
NCT06320990Phase 1Recruiting
- Sponsor
- University of Nebraska
- Start
- Jan 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tamoxifen in pancreatic mucinous cystic neoplasm (MCN), sponsored by University of Nebraska. Primary endpoints: Feasibility, by adherence rate at 6 months and Feasibility, by retention rate at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
pancreatic mucinous cystic neoplasm (MCN)
Beyond the preview
Go deeper on NCT06320990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320990.